Cargando…
Corneal endothelial cell dysfunction: etiologies and management
A transparent cornea is essential for the formation of a clear image on the retina. The human cornea is arranged into well-organized layers, and each layer plays a significant role in maintaining the transparency and viability of the tissue. The endothelium has both barrier and pump functions, which...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293368/ https://www.ncbi.nlm.nih.gov/pubmed/30560230 http://dx.doi.org/10.1177/2515841418815802 |
_version_ | 1783380527585165312 |
---|---|
author | Feizi, Sepehr |
author_facet | Feizi, Sepehr |
author_sort | Feizi, Sepehr |
collection | PubMed |
description | A transparent cornea is essential for the formation of a clear image on the retina. The human cornea is arranged into well-organized layers, and each layer plays a significant role in maintaining the transparency and viability of the tissue. The endothelium has both barrier and pump functions, which are important for the maintenance of corneal clarity. Many etiologies, including Fuchs’ endothelial corneal dystrophy, surgical trauma, and congenital hereditary endothelial dystrophy, lead to endothelial cell dysfunction. The main treatment for corneal decompensation is replacement of the abnormal corneal layers with normal donor tissue. Nowadays, the trend is to perform selective endothelial keratoplasty, including Descemet stripping automated endothelial keratoplasty and Descemet’s membrane endothelial keratoplasty, to manage corneal endothelial dysfunction. This selective approach has several advantages over penetrating keratoplasty, including rapid recovery of visual acuity, less likelihood of graft rejection, and better patient satisfaction. However, the global limitation in the supply of donor corneas is becoming an increasing challenge, necessitating alternatives to reduce this demand. Consequently, in vitro expansion of human corneal endothelial cells is evolving as a sustainable choice. This method is intended to prepare corneal endothelial cells in vitro that can be transferred to the eye. Herein, we describe the etiologies and manifestations of human corneal endothelial cell dysfunction. We also summarize the available options for as well as recent developments in the management of corneal endothelial dysfunction. |
format | Online Article Text |
id | pubmed-6293368 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-62933682018-12-17 Corneal endothelial cell dysfunction: etiologies and management Feizi, Sepehr Ther Adv Ophthalmol Review A transparent cornea is essential for the formation of a clear image on the retina. The human cornea is arranged into well-organized layers, and each layer plays a significant role in maintaining the transparency and viability of the tissue. The endothelium has both barrier and pump functions, which are important for the maintenance of corneal clarity. Many etiologies, including Fuchs’ endothelial corneal dystrophy, surgical trauma, and congenital hereditary endothelial dystrophy, lead to endothelial cell dysfunction. The main treatment for corneal decompensation is replacement of the abnormal corneal layers with normal donor tissue. Nowadays, the trend is to perform selective endothelial keratoplasty, including Descemet stripping automated endothelial keratoplasty and Descemet’s membrane endothelial keratoplasty, to manage corneal endothelial dysfunction. This selective approach has several advantages over penetrating keratoplasty, including rapid recovery of visual acuity, less likelihood of graft rejection, and better patient satisfaction. However, the global limitation in the supply of donor corneas is becoming an increasing challenge, necessitating alternatives to reduce this demand. Consequently, in vitro expansion of human corneal endothelial cells is evolving as a sustainable choice. This method is intended to prepare corneal endothelial cells in vitro that can be transferred to the eye. Herein, we describe the etiologies and manifestations of human corneal endothelial cell dysfunction. We also summarize the available options for as well as recent developments in the management of corneal endothelial dysfunction. SAGE Publications 2018-12-07 /pmc/articles/PMC6293368/ /pubmed/30560230 http://dx.doi.org/10.1177/2515841418815802 Text en © The Author(s), 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Feizi, Sepehr Corneal endothelial cell dysfunction: etiologies and management |
title | Corneal endothelial cell dysfunction: etiologies and
management |
title_full | Corneal endothelial cell dysfunction: etiologies and
management |
title_fullStr | Corneal endothelial cell dysfunction: etiologies and
management |
title_full_unstemmed | Corneal endothelial cell dysfunction: etiologies and
management |
title_short | Corneal endothelial cell dysfunction: etiologies and
management |
title_sort | corneal endothelial cell dysfunction: etiologies and
management |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293368/ https://www.ncbi.nlm.nih.gov/pubmed/30560230 http://dx.doi.org/10.1177/2515841418815802 |
work_keys_str_mv | AT feizisepehr cornealendothelialcelldysfunctionetiologiesandmanagement |